BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
75 hedge funds and large institutions have $32.1M invested in BRAINSTORM CELL THERAPUTC in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 26 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
0.19% less ownership
Funds ownership: 1.76% → 1.57% (-0.19%)
17% less funds holding
Funds holding: 90 → 75 (-15)
17% less capital invested
Capital invested by funds: $38.5M → $32.1M (-$6.47M)
35% less call options, than puts
Call options by funds: $3.17M | Put options by funds: $4.87M
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.08M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.48M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$688K |
| 4 |
Two Sigma Advisers
New York
|
+$606K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.36M |
| 2 |
Morgan Stanley
New York
|
-$882K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$762K |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$588K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$434K |
BCLI Hedge Fund Activity: Q1 2021 in Review
75 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2021, worth a combined $32.1M — down 17% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BCLI and 11 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 24 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.08M. The largest seller was Voloridge Investment Management, cutting an estimated $1.36M.
- 75 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2021, down from 90 in Q4 2020.
- Funds reported $32.1M of BRAINSTORM CELL THERAPUTC stock for Q1 2021, down 17% quarter-over-quarter.
- 11 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2021 and 26 closed out, a net change of -15 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2021 was JP Morgan Chase, an estimated $2.08M added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2021 was Voloridge Investment Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2021.